Clinical trials · Massachusetts
Metastatic Cancer clinical trials in Massachusetts
We’re tracking 188 recruiting metastatic cancer studies with a site in Massachusetts — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Massachusetts
- NCT04900818RecruitingPhase 1
Givastomig for advanced solid cancers, including gastric and pancreas
This Phase 1 trial tests how safe and effective givastomig (TJ033721) is for advanced or metastatic solid tumors. It may help people whose cancer has grown despite standard treatment, or—if in the combination parts—specific cancers that meet certain lab test and tumor-marker requirements.
Boston, MassachusettsAges 18 years+ - NCT06820463RecruitingPhase 2
Study of telisotuzumab adizutecan plus chemo for metastatic colorectal cancer
This trial tests a new drug combination for people with metastatic colorectal cancer. The study includes an experimental antibody-drug conjugate (telisotuzumab adizutecan) plus standard chemotherapy and targeted therapies, to see if it works better than current options.
Boston, MassachusettsAges 18 years+ - NCT07524855RecruitingPhase 1
Study of a new drug for metastatic breast cancer
This trial tests an experimental drug called JNJ-101684362 (HLD-0117) for people with metastatic breast cancer that has not responded to other treatments. It may help by targeting cancer cells in a new way, and the study will check if it is safe and effective.
Boston, MassachusettsAges 18 years+ - NCT07228832RecruitingPhase 3
Study of two drugs with chemo for advanced colorectal cancer
This clinical trial tests a new drug, ivonescimab, against an approved drug, bevacizumab. Both are given with standard chemotherapy (FOLFOX) for people with advanced colorectal cancer that has not been treated yet with chemo or other drugs.
Boston, MassachusettsAges 18 years+ - NCT07181161RecruitingPhase 1/Phase 2
Testing a new drug for metastatic prostate cancer
This trial tests an investigational drug (AZD0516) alone or with other treatments in men with prostate cancer that has spread to other parts of the body and is no longer responding to hormone therapy. It aims to see if the drug can help control the cancer.
Boston, MassachusettsAges 18–130 - NCT06901531RecruitingPhase 3
Study of zolbetuximab with pembrolizumab and chemo for gastric cancer
This trial tests a new combination of drugs (zolbetuximab, pembrolizumab, and chemotherapy) for people with advanced stomach or gastroesophageal junction cancer. It may be an option if your tumor has certain proteins (CLDN18.2 and PD-L1) and you haven't had chemotherapy for advanced disease.
Boston, MassachusettsAges 18 years+ - NCT06800313RecruitingPhase 1/Phase 2
A study of HLD-0915 for metastatic prostate cancer
This trial tests a new drug called HLD-0915 in men with prostate cancer that has spread. It aims to see how well the drug works and if it's safe.
Boston, MassachusettsAges 18 years+ - NCT06795529Recruiting
Palliative care support for metastatic breast cancer
This study tests a palliative care program designed to improve quality of life for people with metastatic breast cancer. It may help you better manage symptoms and coordinate care with your oncology team.
Boston, MassachusettsAges 18 years+ - NCT06267729RecruitingPhase 1/Phase 2
A new cell therapy for advanced prostate cancer
This trial tests a new cell therapy (AZD0754) for metastatic prostate cancer that has stopped responding to standard hormone therapy and chemotherapy. It’s looking for people whose cancer has gotten worse despite prior treatments, and who are still in fairly good health.
Boston, MassachusettsAges 18–130 - NCT05894239RecruitingPhase 3
Tested targeted drug for HER2-positive breast cancer with PIK3CA changes
This Phase 3 study tests inavolisib plus Phesgo versus placebo plus Phesgo in people whose breast cancer has both HER2-positive and PIK3CA-mutated tumor markers. The goal is to see if adding inavolisib improves how well the treatment controls the cancer and how safe it is.
Boston, MassachusettsAges 18 years+ - NCT05216432RecruitingPhase 1
RLY-2608 for PIK3CA-mutant advanced solid tumors and breast cancer
This early study (Phase 1) tests RLY-2608, a targeted cancer drug for tumors with a PIK3CA mutation. It studies the drug alone and combined with hormone therapy (and sometimes CDK4/6 or CDK4 medicines) to see safety, dose, and whether it can shrink tumors.
Boston, MassachusettsAges 18 years+ - NCT07085767RecruitingPhase 3
Palazestrant and ribociclib for first-line advanced breast cancer
This trial tests a new drug (palazestrant) combined with ribociclib for people with a common type of advanced breast cancer that is estrogen receptor-positive and HER2-negative. You may qualify if you haven't had treatment for advanced disease and your cancer has either just been found or came back long after completing hormone therapy.
Burlington, MassachusettsAges 18 years+ - NCT06982521RecruitingPhase 3
Comparing two drug combinations for advanced breast cancer
This trial tests two different combinations of medicines for people with a certain type of advanced breast cancer (HR-positive, HER2-negative) that has a specific gene change called PIK3CA. The goal is to see which combination is better at slowing down the cancer.
Boston, MassachusettsAges 18 years+ - NCT06138561Recruiting
Bladder cancer treatment study for older adults
This study looks at how well different treatments work for older adults with bladder cancer that has spread and who cannot take cisplatin. It also checks if geriatric assessments help guide care.
Boston, MassachusettsAges 65 years+ - NCT04929223RecruitingPhase 1
Targeted drug study for metastatic colon or rectal cancer
This Phase 1 study tests targeted cancer treatments in people with metastatic colorectal cancer, using genetic “biomarker” results to match you to the right treatment group. It focuses first on safety, and also looks for early signs the treatment may work in specific tumor subgroups.
Boston, MassachusettsAges 18 years+ - NCT06239220RecruitingPhase 2
Combination immunotherapy for advanced head and neck cancer
This trial tests a combination of three immunotherapy drugs (PD-L1 t-haNK, NAI IL-15sa, and cetuximab) for people with head and neck squamous cell carcinoma that has spread or cannot be cured. The goal is to see if this treatment can shrink tumors or slow the disease.
Boston, MassachusettsAges 18 years+ - NCT05142800Recruiting
Screening for Lymphedema in Breast Cancer Targeted Therapy
This study is looking at whether targeted therapy for breast cancer changes the risk of arm swelling (lymphedema). It is a screening trial that uses a machine to measure arm size and check for any swelling early on.
Boston, MassachusettsAges 18–80 - NCT06324357RecruitingPhase 1/Phase 2
Zongertinib for HER2-positive cancers that have spread
This trial tests a new pill called zongertinib, alone or with other drugs, for people with HER2-positive cancers (like breast, stomach, or colorectal cancer) that have spread and are no longer responding to standard treatments. The goal is to find the best dose and see if it can help shrink tumors or slow the disease.
Boston, MassachusettsAges 18 years+ - NCT06957691RecruitingPhase 2
Fezolinetant for hot flashes in men on hormone therapy
This study tests a medication called fezolinetant to see if it reduces hot flashes in men undergoing hormone therapy for prostate cancer. If you experience frequent hot flashes, this treatment might help alleviate them.
Boston, MassachusettsAges 40 years+ - NCT04787744RecruitingPhase 2/Phase 3
Test standard prostate cancer treatment with or without targeted spot radiation
This study tests whether adding targeted local treatment (like radiation to a few spots seen on scans) improves outcomes for some people with limited (oligometastatic) prostate cancer. It compares standard systemic therapy alone versus standard therapy plus PET-scan–guided spot treatment.
Boston, MassachusettsAges 18 years+ - NCT07222215RecruitingPhase 2
Capacitabine with or without elacestrant for ER+ breast cancer
This trial tests if adding a new oral targeted therapy (elacestrant) to standard chemotherapy (capecitabine) works better than chemotherapy alone for people with a specific type of advanced breast cancer that is hormone-sensitive (ER-positive) and has stopped responding to hormone therapy.
Boston, MassachusettsAges 18 years+ - NCT07227415RecruitingPhase 1/Phase 2
Study of a new drug for advanced kidney cancer
This trial tests a new drug, PF-08634404, alone or with other cancer treatments, for adults with advanced kidney cancer that has not been treated before. It aims to see if the drug can help shrink tumors or stop them from growing.
Boston, MassachusettsAges 18 years+ - NCT07491445RecruitingPhase 3
Daraxonrasib plus chemo for first-line metastatic pancreatic cancer
This trial tests a new targeted therapy (daraxonrasib) combined with standard chemotherapy as the first treatment for people whose pancreatic cancer has spread. The goal is to see if this combination can help shrink or control the cancer better than chemotherapy alone.
Boston, MassachusettsAges 18 years+ - NCT05489211RecruitingPhase 2
Testing a cancer drug for advanced solid tumors
This Phase 2 study tests the drug Dato-DXd (alone or with other cancer medicines) in people with advanced solid tumors. It looks for tumor shrinkage and how safely the treatment can be given.
Boston, MassachusettsAges 18–130
Metastatic Cancer trials by city in Massachusetts
Where these studies are running in Massachusetts
Institutions with a site for the recruiting metastatic cancer studies listed above.
- Dana-Farber Cancer Institute · 10 studies
- Massachusetts General Hospital · 5 studies
- Brigham and Women's Hospital · 3 studies
- Research Site · 3 studies
- Clinical Study Site
- Clinical Trial Site
- Dana Farber Mass General Brigham Cancer Care Inc
- Dana Farber/Harvard Cancer Center
What taking part in a metastatic cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Metastatic Cancer trials in other states
Common questions
- Are there metastatic cancer clinical trials in Massachusetts?
- Yes. We're currently tracking 188 recruiting metastatic cancer studies with a site in Massachusetts, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a metastatic cancer study in Massachusetts?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Massachusetts to take part?
- Not necessarily. These studies have a site in Massachusetts, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a metastatic cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New metastatic cancer studies open in Massachusetts regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.